Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topifegastim versus other PEG-rhG-CSFs for prevention of neutropenia in non-small cell lung cancer after radiotherapy or chemotherapy
ChiCTR2400083502Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of taipegastim in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Incidence of grade 3/4 neutropenia during the first cycle of chemotherapy and Incidence of grade 3/4 neutropenia during radiotherapy cycles. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
taipegastim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083502.